The leadership team at Catamaran Bio has deep expertise in cell therapy research and product development and the team includes.

Catamaran bio funding. She brings more than 16 years of experience in research and drug discovery in biotech and large pharma. It was founded in 2020 and headquartered in Cambridge Massachusetts. Catamaran Bio is a biotechnology company that specializes in allogeneic immune cell therapies.

Vipin Suri PhD MBA Chief Scientific Officer who has more than 20 years of biopharmaceutical experience including as a co-founder of Obsidian Therapeutics and Serien formerly Raze Therapeutics and earlier in R. This deal was done in Cash. The company engages in using genetic engineering of natural killer cells to target a number of therapeutic areas with high unmet needs enabling medical practitioners and individuals to procure therapies for treating their conditions.

Catamaran Bio has 26 employees at their 1 location and 42 m in total funding. Sofinnova Partners and Lightstone Ventures co-led the Series A round that is part of the launch financing with participation by founding investor SV Health Investors as well as Takeda Ventures and Astellas Venture Management. Our proprietary capabilities enable us to harness the natural cancer-fighting properties of NK cells and enhance and tailor their effectiveness with the power of synthetic biology and innovative non-viral cell engineering.

Was acquired by OptumRx for 128B on Mar 30 2015. Vipin Suri PhD MBA Chief Scientific Officer who has more than 20 years of biopharmaceutical experience including as a co-founder of Obsidian Therapeutics and Serien formerly Raze Therapeutics and earlier in R. Prior to Catamaran Celeste served as Vice President of Cell Therapy at Obsidian Therapeutics where she led.

This funding round was led by Lightstone Ventures and Sofinnova Partners and included participation from the founding investor of Catamaran Bio SV health investors. It offers cell therapy company developing allogeneic off-the-shelf products for patients with an unmet medical need. Catamaran Bio Based in Part on U of M Research Soars with Early Funding December 3 2020 SV Health Investors a top-tier venture capital firm and one of the longest-tenured healthcare investment managers in the world supports Catamaran Bio showing the Twin Cities potential for its contribution to biotechnology advancements.

The leadership team at Catamaran Bio has deep expertise in cell therapy research and product development and the team includes. Natural killer cell NIAID Flickr 23 Nov. Celeste joined Catamaran as Senior Vice President Research in June 2020.